
    
      This is a randomized, open-label, Phase I/II study of intravitreally administered ranibizumab
      for the treatment of tube patency in glaucoma patients.

      Thirty (30) patients with severe glaucoma requiring tubes will be randomized (2:1) to either
      ranibizumab or observation.

      Consented, enrolled subjects assigned to the treatment group will receive open-label
      intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly
      x 2 more injections Sham intravitreal injections for the observation group will NOT be
      performed.

      Study periods:

      Study start date: May 1st, 2007 (estimated) Enrollment period: 6-8 months (estimated)
      Follow-up period: 6 months Study end Date: December 1st, 2010 (estimated)
    
  